JN1806型重组小鼠Legumain(天冬酰胺肽链内切酶)

特别声明：本产品及我公司所售其他产品均为科研类试剂产品，严禁用于药物、医疗及其他非科研用途。

JN1806型重组小鼠Legumain(天冬酰胺肽链内切酶)(天冬*酸内肽酶)厂家由专业试剂供应商北京百奥莱博提供，用于生化研究，本产品质量好，且极具价格优势，深为用户称道，了解更多重组小鼠Legumain(天冬酰胺肽链内切酶)(天冬*酸内肽酶)等重组蛋白产品请联*(代"系")我司咨询订购。

名称：JN1806型重组小鼠Legumain(天冬酰胺肽链内切酶)(天冬*酸内肽酶)厂家
英文名：Recombinant Mouse Legumain/Asparaginyl Endopeptidase
规格：10μg|50μg|500μg|1mg
品牌：百奥莱博
本品由我们的哺乳动物细胞表达系统制备而成，目的基因编码的Val18-Tyr435在C端含有His标签。

Legumain质量控制：＞95%(还原性SDS-PAGE)

Legumain制剂：液体

Legumain保存：收到货后请置于-20℃，可保存6个月，避免反复冻融。

关于Legumain：
Mouse Legumain,also known as LGMN, is a cysteine protease belonging to peptidase family C13 and is expressed in kidney and placenta abundantly. LGMN has a strict specificity for hydrolysis of asparaginyl bonds. It can also cleave aspartyl bonds slowly, especially under acidic conditions. The mammalian legumain is involved in the processing of proteins for MHC class II antigen presentation in the lysosomal/endosomal system. It plays a role in the regulation of cell proliferation via its role in EGFR degradation. Legumain deficiency causes the accumulation of pro-Cathepsins B, H and L, another group of lysosomal cysteine proteases. Overexpression of Legumain in tumors is significant for invasion/metastasis. Mammalian legumain is inhibited by iodoacetamide and maleimides. Legumain activation appears to be autocatalytic and can be triggered by acidic pH.


关于JN1806型重组小鼠Legumain(天冬酰胺肽链内切酶)(天冬*酸内肽酶)厂家的更详细说明，请致电我公司咨询，我们将以最饱满的热情为您提供解答，此外，我公司专业供应下列产品：

·重组人细胞毒性T淋巴细胞蛋白4(CTLA-4)(CD152)
编号：JN1568
英文名称：Recombinant Human Cytotoxic T-lymphocyte protein 4
规格：10μg|50μg|500μg|1mg
本品由我们的哺乳动物细胞表达系统制备而成，目的基因编码的Lys36-Asp161在C端含有His标签。

CTLA-4/CD152质量控制：＞95%(还原性SDS-PAGE)

CTLA-4/CD152制剂：冻干品

CTLA-4/CD152保存：
冻干蛋白置于-20℃以下可长期保存，室温条件下可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天，可分装后置于-20℃保存三个月。

CTLA-4/CD152复溶：
打开试剂管前请先离心。
复溶浓度推荐大于100 μg/ml。
冻干蛋白请溶于ddH2O。
复溶后，请根据用量分装冻存，避免反复冻融。

关于CTLA-4/CD152：
Cytotoxic Tlymphocyte 4(CTLA-4,CD152), is a type I transmembrane T cell inhibitory molecule that is a member of the Ig superfamily. Human or mouse CTLA4 cDNA encodes 223 amino acids (aa) including a 35 aa signal sequence, a 126 aa extracellular domain (ECD) with one Ig-like V-type domain, a 21 aa transmembrane (TM) sequence, and a 41 aa cytoplasmic sequence.It is widely expressed with highest levels in lymphoid tissues. CD28 and CTLA-4, together with their ligands, B7-1 and B7-2, constitute one of the dominant costimulatory pathways that regulate T and B cell responses. CD28 and CTLA-4 are structurally homologous molecules that are members of the immunoglobulin (Ig) gene superfamily. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T Cells and may play an important role in their functions. Tcell activation through the Tcell receptor and CD28 leads to increased expression of CTLA4.


JN1806型重组小鼠Legumain(天冬酰胺肽链内切酶)(天冬*酸内肽酶)厂家关键词：JN1806,重组小鼠Legumain蛋白,重组小鼠天冬酰胺肽链内切酶,重组小鼠天冬*酸内肽酶


·Taq连接酶
编号：JN0080
英文名称：Taq DNA Ligase
规格：1000U
  本酶是从Thermus aquaticus HB8中克隆出的DNA连接酶，利用基因重组技术，在大肠杆菌中进行表达后经多次纯化分离而得。Taq DNA连接酶能够催化磷酸二酯键的形成，使杂交到同一互补靶DNA链上的两条契合寡核苷酸链的5´-磷酸末端和3´-羟基末端通过磷酸二酯键连接。这个连接反应只有当两条寡核苷酸链与互补靶DNA完全配对并且两条寡核苷酸链之间没有空隙的条件下才可发生。因此，可以用它来检测单碱基替换。在 45℃-65℃ 范围内，Taq DNA连接酶均有活性。

质量保证：经多次柱纯化，SDS-PAGE胶检测仅可见清晰单一的目的条带，严格质量控制，确保该产品具有最高的活性和纯度。

活性定义：50μl反应体系中，45℃反应条件下，15分钟能使 50%的12bp粘性末端片段发生连接所需要的酶量。12bp粘性末端来自于BstEII消化1μg λDNA。


JN1806型重组小鼠Legumain(天冬酰胺肽链内切酶)(天冬*酸内肽酶)厂家关键词：JN1806,重组小鼠Legumain蛋白,重组小鼠天冬酰胺肽链内切酶,重组小鼠天冬*酸内肽酶


·重组人白介素27(IL-27)
编号：JN1080
英文名称：Recombinant Human Interleukin-27
规格：10μg|50μg|500μg|1mg
本品由我们的哺乳动物细胞表达系统制备而成，目的基因编码的Arg21-Lys229&Phe29-Pro243 ~ 在C端含有His标签。

IL-27质量控制：＞95%(还原性SDS-PAGE)

IL-27制剂：冻干品

IL-27保存：
冻干蛋白置于-20℃以下可长期保存，室温条件下可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天，可分装后置于-20℃保存三个月。

IL-27复溶：
打开试剂管前请先离心。
复溶浓度推荐大于100 μg/ml。
冻干蛋白请溶于ddH2O。
复溶后，请根据用量分装冻存，避免反复冻融。

关于IL-27：
IL-27 is a heterodimeric cytokine which belongs to the IL-6/IL-12 family of long type I cytokines. It is expressed on monocytes, endothelial cells and dendritic cells. IL-27 is an early product of activated antigen-presenting cells and drives rapid clonal expansion of naive CD4(+) T cells and plays a role in the early regulation of Th1 cells initiation which drives efficient adaptive immune response. IL-27 potentiates the early phase of TH1 response and suppresses TH2 and TH17 differentiation. It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1 cell commitment. IL-27 has an antiproliferative activity on melanomas through WSX-1/STAT1 signaling. Thus, IL-27 protein may be an attractive candidate as an antitumor agent applicable to cancer immunotherapy. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. Indeed IL27 alone is also able to inhibit the production of IL17 by CD4 and CD8 T-cells. IL-27 has also an effect on cytokine production. It suppresses proinflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3. Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T-cells. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9.

我公司生产供应销*(代"售")的重组蛋白正全品类优惠促销，十分期待您的咨询选购JN1806型重组小鼠Legumain(天冬酰胺肽链内切酶)(天冬*酸内肽酶)厂家。